Key result
Embolic protection devices during TAVI may reduce silent ischemic lesions but show no clinical stroke benefit.
Why the study?
Does the use of embolic protection devices (EPD) reduce silent ischemic and clinically evident cerebrovascular events in patients undergoing TAVI?
Population
Patients undergoing transcatheter aortic valve implantation (TAVI)
Comparison
Embolic protection devices (EPD) during TAVI vs No embolic protection device (no-EPD) during TAVI
Design
Meta-analysis
Authors
Loading...
No clinical benefit on stroke or mortality with EPD in TAVI; leaves open surrogate effects pending higher-quality trials.
Meta-Analysis
Does the use of embolic protection devices (EPD) reduce silent ischemic and clinically evident cerebrovascular events in patients undergoing TAVI?
p-value: p==0.05
The use of embolic protection devices during TAVI may reduce the volume of silent ischemic lesions but does not appear to significantly reduce clinically evident stroke or mortality based on current low-quality evidence.
Bagur et al. (2017) conducted a meta-analysis in Transcatheter aortic valve implantation (TAVI). Embolic protection devices (EPD) vs. No EPD was evaluated on Silent ischemic and clinically evident cerebrovascular events (p==0.05). Embolic protection devices during TAVI may reduce the volume of silent ischemic lesions (P=0.05), but very low quality evidence shows no significant difference in clinical stroke or mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: